Calls for papers
-
Honeywell has begun large scale manufacturing of Solstice Air HFO-1234ze(E), a low global-warming-potential (GWP) MDI propellant, at a facility located in Baton Rouge, LA, USA, the company said. In February 2022, AstraZeneca announced that it… Read more . . .
-
Dutch intranasal vaccine developer and CDMO Intravacc said that it has received an award of up to $14.6 million from the US National Institute of Allergy and Infectious Diseases (NIAID) to support development of an… Read more . . .
-
Synairgen has announced that the Phase 2 ACTIV-2 trial of SNG001 inhaled interferon-beta-1a in non-hospitalized COVID-19 patients failed to show a statistically significant reduction in hospitalization, viral load, safety, or resolution of symptoms compared to placebo,… Read more . . .
-
Inhaled flecanide developer InCarda Therapeutics has named former Arena Pharmaceuticals executive Robert Lisicki as CEO, succeeding Grace Colón who the company says “intends to pursue other leadership opportunities within the life science space” but will continue… Read more . . .
-
Pfizer has completed its acquisition of Biohaven Pharmaceutical, including Biohaven’s intranasal zavegepant (BHV-3500) calcitonin gene-related peptide (CGRP) receptor antagonist, the company said. Pfizer announced that it had acquired the ex-US rights to zavegepant and Nurtec… Read more . . .
-
Startup inhaled drug developer AeroRx Therapeutics and nebulizer maker HCmed Innovations have announced that they will partner on development of a nebulized LABA/LAMA inhalation solution for the treatment of COPD. AeroRx is a spinoff of… Read more . . .
-
Registration is open for DDL 2022, which will be the first in-person Drug Delivery to the Lungs meeting since the beginning of the COVID-19 pandemic. The meeting will take place December 7-9 and is expected… Read more . . .
-
Odyssey Health announced that it has completed its Phase 1 study of PRV-002, a novel intranasal synthetic neurosteroid powder formulation that the company is developing for the treatment of concussion, and said that the results… Read more . . .
-
After announcing a deal with Recipharm for development of two inhaled drugs (TRB-1 and TRB-2) earlier this year, Transpire Bio says that it has signed an agreement with the CDMO for development of an additional… Read more . . .
-
Ocugen announced that it has acquired US, European, and Japanese rights to an intranasal COVID-19 vaccine developed at Washington University in St. Louis. In September 2020, Bharat Biotech announced that it had acquired rights to… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland
April 27-30: RDD Europe 2027, Antibes, France
May 12-13: USP Joint Workshop: Quality and Product Performance Testing of Orally Inhaled and Nasal Drug Products, Rockville, MD, USA
June 30: RespireX 2027, Boston, MA, USA